Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
Date:2/12/2013

', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words.  Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011, each of Auxilium's Quarterly Reports on Form 10-Q for the three months ended September 30, 2012, June 30, 2012 and March 31, 2012 and Auxilium's preliminary prospectus supplement and Current Report on Form 8-K, each filed with the Securities and Exchange Commission (the "SEC") on January 23, 2013. While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so.  Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov.  There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

For More Information, Contact:

Contacts:
James E. Fickenscher /CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr. / VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900 
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... a significant percentage of Americans, the answer is no, ... the science of the very small. , Addressing scientists ... of the American Association for the Advancement of Science, ... sciences communication, presented new survey results that show religion ...
... that Significantly Raises HDL "Good" Cholesterol and Lowers ... ... ABBOTT PARK, Ill., Feb. 15 Today, Abbott,received U.S. Food and ... widely prescribed cholesterol,therapies, Niaspan(R) (Abbott,s proprietary niacin extended-release) and,simvastatin. SIMCOR is ...
... Pharma (Oxford, UK), a,Vaccinex collaboration partner, has announced ... discovered by Vaccinex, to,GlaxoSmithKline., According to the ... an up-front,license fee, development milestones, and royalties on ... develop and commercialize,OP-R003 for the treatment of rheumatoid ...
Cached Biology Technology:Religion colors Americans' views of nanotechnology 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 3Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 4Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 5Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 6Vaccinex Antibody Licensed to GlaxoSmithKline 2
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
Breaking Biology News(10 mins):
... factor only just beginning to be appreciated by social ... Terje Tvedt, of the Universities of Oslo and Bergen, ... role in shaping societies throughout human history. Speaking at ... in October, Tvedt proposed that social scientists and historians ...
... vice president for technology development at NJIT, has been ... and Technology to assist faculty researchers with the most ... $50,000. The money, known as Gap grants, is ... idea and a commercial product. Sixteen grants ...
... Carolina at Chapel Hill researchers using brain imaging of ... that may mark the onset of autistic symptoms is ... in funding. , The Infant Brain Imaging Study ... awarded $10 million in 2007 by the National Institutes ...
Cached Biology News:Using water to understand human society, from the industrial revolution to global trade 2Using water to understand human society, from the industrial revolution to global trade 3Moving new technologies from the lab to the marketplace 2Moving new technologies from the lab to the marketplace 3UNC expands brain imaging study of infants at risk for autism 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Cyno macaque plasma and serum - various quantities available...
Biology Products: